Audit: QRS - Topical Dutasteride for Hair Regrowth
Audit conducted on 21/09/2026 21:02 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 85 |
| Failed | 0 |
| N/A | 8 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Spot-checked every populated span. Protocol cells trace to ER Therapeutic Protocol (ER 330, 332, 334); time cells to ER Practical Considerations (ER 387) and Monitoring Protocol & Defining Success (ER 415); marker rows and cadence to the ER biomarker table (ER 419-425) and ER 415; qualitative items to ER 429-433. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | The ER’s hedges are carried over: “Sparsely studied” in at-a-glance mirrors ER 459; Speculative-tier framing is preserved for both benefits and risks. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications remain absolute exclusions (QRS 543-549) exactly as ER 302-308 states them; interactions remain interactions, not prohibitions. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | All stop_items come from the ER’s “Populations who should avoid” list; all caution_items from the ER’s interaction bullets. No Benefit- or Risk-Modifying Factor content appears in the gates. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, NCT numbers, author names or brand names appear anywhere in the QRS; named drugs (tamsulosin, verapamil, minoxidil, etc.) are all present in ER 282-298. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind in the QRS body. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Measured, evidence-weighted register matching the ER, including the ER’s own caveat about the commercial tilt of the evidence base (ER 459 → QRS 433). |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Tiered benefits/risks, concrete protocols and measurable targets give the reader an actionable frame without overselling. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | All content is stated descriptively (“one session every 3 months after an initial closer-spaced induction”), never as instruction to an individual. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No imperatives or recommendations; the footer disclaimer is the template’s own. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Monitoring cadence and qualitative items use passive, descriptive constructions (“repeated at 3 months”, “photographed monthly under identical conditions”). |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the QRS. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms are limited to those the ER requires (dihydrotestosterone, 5-alpha reductase, CYP3A4); the lede replaces them with plain-language equivalents. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every gate, tier and table cell is a stripped-down fact; no explanatory clauses survive. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed: no “you”/”your” in the QRS. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Content assumes a reader willing to track trichoscopic density, run a functional biomarker panel and source a compounded preparation. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Quarterly intradermal sessions, weekly shed counts and monthly standardized photographs are presented without hedging on inconvenience. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Functional biomarker targets (e.g., ferritin 70-150 ng/mL, TSH 0.5-2.0 mIU/L) are tighter than conventional lab ranges, signalling the optimizing audience. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The at-a-glance names both the efficacy shortfall against the oral route and the commercial tilt, which is the decision-relevant weighting for this audience. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | The string “anti-aging” does not occur in the QRS. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | The lede uses “injections”, “oral dutasteride” and “placebo” rather than the ER conclusion’s lay renderings (“dummy treatment”, “the oral capsule”); “adverse effects” is used throughout the risks card. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed headings match the template byte-for-byte (QRS 440, 477, 519, 540, 554, 575, 595, 599-601, 692). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 34 distinct template variables are present; marker_#* and qualitative_item# are instantiated 7 and 5 times respectively. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | A normalized structural diff against the template shows only variable fills and the intended row repetitions; head, styles, footer and website=”” spans are untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No section of the source ER is empty; the two empty tiers (Benefits Medium, Risks High) are governed by 12.5 and 13.5 instead. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol labels are the ER’s bold labels verbatim: “Standard intradermal protocol”, “Topical solution protocol”, “Microneedling-assisted protocol” (ER 330-334). Marker names match the ER biomarker column verbatim. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | No invented labels; time-to-effect labels use the ER’s own wording (“shedding … slows”, “density is stable”, “measurable density gain”, ER 387, 415). |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | Zero emoji characters in the file; the ER’s ⭕️ and ⚠️ markers were stripped when the Low tiers were carried over. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every carried item is reduced to its ER heading or label with explanation, magnitude and citation removed; marker 7’s target was shortened from the ER wording to fit. No section was extended beyond the template’s single-page structure. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | QRS 2-14: the metadata comment immediately follows the doctype on line 1. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening “—” at QRS 3, closing “—” at QRS 13. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; none of its values are repeated in a rendering element. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:02" is quoted, correctly so because the value contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | QRS 4: er_filename: topical_dutasteride_hair_2026-0921-1818_Opus_ER.md, matching the ER’s own filename field. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | QRS 5: qrs_prompt_version: 26.9.11, matching the version badge in QRS.md. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | QRS 6: qrs_creation_date: 2026-0921-2050, correct format. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | QRS 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | QRS 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | QRS 9 matches the actual filename topical_dutasteride_hair_2026-0921-1818_Opus_QRS.html. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys; no stray whitespace or unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | QRS 22: “Topical Dutasteride for Hair Regrowth - Quick Reference Sheet”; canonical_topic at ER 8 matches; no characters require encoding. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | QRS 417: “Topical Dutasteride for Hair Regrowth”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | QRS 421: 09/21/2026, the correct reformatting of 2026-0921-2050. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | QRS 425: “Opus 5”, matching the frontmatter value. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header contains only the title and the template subline; the ER’s “Also known as” line was not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | QRS 433 condenses all three Conclusion paragraphs (ER 455-459): intent, controlled evidence and its ranking, harm profile, and the state of the evidence base. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 57 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Mechanism/intent → ER 455; three small short controlled studies → ER 455, 457; pooled ranking below oral → ER 457; procedural harms → ER 457; sparsely studied with commercial tilt → ER 459. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | Uses “the hair-shrinking hormone” rather than dihydrotestosterone/DHT; no acronyms, no tier or evidence-class jargon. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | Only “Three small, short controlled studies” in the aggregate; no names, years, n or p-values. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numbers other than the count of studies. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All seven items map to the “Populations who should avoid Topical Dutasteride” list at ER 300-308. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All seven ER exclusion bullets are present, none added (QRS 543-549). |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Seven discrete <li> elements inside the stop_items span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every “because…”/”where…”/”in whom…” clause from ER 302-308 is stripped (e.g., the hypospadias rationale, the pillowcase-residue clause, the “no dosing, safety or developmental data exist” clause). |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “(Child-Pugh Class C)”, “within 12 months of a prostate biopsy”, “under 18 years” and “until healed” are all retained (QRS 546-549). |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER names seven such populations, and the section is correctly populated rather than empty. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All nine items map to the interaction bullets at ER 282-298. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All nine ER interaction bullets are present; none duplicates a contraindication. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Nine discrete <li> elements inside the caution_items span (QRS 557-565). |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Monitor/Caution verdicts, mechanisms and mitigations are all stripped; the em-dash gloss inside the alpha-blocker parenthesis (“— drugs that relax the prostate and blood vessels”) is removed. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Named example drugs are retained for every bullet that has them, including the NSAID list pulled from the ER body into the analgesics item (ER 292). |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in this section. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER names nine such interactions, and the section is correctly populated rather than empty. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells come from ER Therapeutic Protocol bullets at ER 330, 332 and 334. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | The three administrable regimens (intradermal, daily topical solution, microneedling-assisted) are selected ahead of the ER’s contextual bullets on competing approaches, popularisers and timing. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies three or more distinct actionable aspects, and all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine cells carry ER-derived content; concentrations, volumes, grid spacing, session intervals and durations match ER 330-334 exactly. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Shedding slowing at 2-3 months (ER 387), density stable at 6 months and measurable density gain at 12 months (ER 415) are the only time-to-effect milestones the ER states. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Ordered from the largest related benefit (measurable density gain, the ER’s sole High benefit) through stabilization to the earliest and smallest signal, reduced shedding. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER provides three distinct time-to-effect aspects, and all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine cells populated; the sub-lines quote the ER’s fixed-point baseline, photographic/trichoscopic reassessment and hair-cycle rationale. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER does provide time-to-effect information (ER 387, 415), so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | Tiers map to the ER headings at ER 154 (High), 166 and 172 (Low) and 180 (Speculative). |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present (QRS 521-533). |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each entry is the bare ER heading; all Magnitude figures (62.8% vs 17.5%, 34.5% vs 55.6%, 541-patient cohort) are omitted. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses in any benefits entry; the ER’s “⭕️ Not Central to Hair Regrowth” flag on the Low benefit is dropped. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | benefits_medium carries style="display: none" with an HTML comment citing ER 162 (“No benefit sits at Medium”); no empty-state text is rendered. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | Tiers map to ER 210 (Medium), 218/224/230 (Low) and 238-264 (Speculative). |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present (QRS 577-589). |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each entry is the bare ER heading; the 45.5% pain frequency, the RR 1.37 (95% CI 0.81-2.32) and all cohort sizes are omitted. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parentheses in any risks entry; the ER’s “⚠️ Conflicted” flag on the sexual adverse effects heading is dropped. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | risks_high carries style="display: none" with an HTML comment citing ER 206 (“No risk reaches High”); no empty-state text is rendered. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Table and cadence come from ER Monitoring Protocol & Defining Success (ER 415-425). |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All seven ER biomarker rows are present in order: serum dihydrotestosterone, total testosterone, prostate-specific antigen, alanine aminotransferase, ferritin, thyroid-stimulating hormone, trichoscopic hair density, with targets and rationales verbatim. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | QRS 686 reproduces the ER’s full schedule: baseline, 3 months, 6 months, then 6-12 monthly bloods and annual photographs (ER 415). |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Items come from the “Qualitative markers worth tracking alongside the numbers” list at ER 429-433. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All five ER qualitative markers are carried over verbatim (QRS 695-707). |
Issues 21/09/2026 21:02
Pass rate 100.00%. No issues found.
Issues 21/09/2026 20:59
- 2.15 — Colloquial “dummy treatment” in lede: [at_a_glance] (line 433) reads “found more regrowth than dummy treatment”, a consumer-grade rendering of “placebo”; 2.15 requires formal clinical terminology on every surface including the lede, and the text is not a direct quote.
Fixes 21/09/2026 20:59
- 2.15 — Colloquial “dummy treatment” in lede: Replaced “dummy treatment” with “placebo” in [at_a_glance], so the lede uses the formal clinical term.
Issues 21/09/2026 20:54
- 9.4 — Drug list attached to wrong half: The Key Interactions item at QRS line 562 reads “Over-the-counter analgesics and alcohol-containing scalp products (ibuprofen, naproxen, aspirin)”; the ER label (line 292) carries no parenthesis, and as placed the examples read as alcohol-containing scalp products rather than as the analgesics they are.
Fixes 21/09/2026 20:54
- 9.4 — Drug list attached to wrong half: Moved the example list so it follows the term it belongs to, changing “Over-the-counter analgesics and alcohol-containing scalp products (ibuprofen, naproxen, aspirin)” to “Over-the-counter analgesics (ibuprofen, naproxen, aspirin) and alcohol-containing scalp products”.